BRA
ABBV icon

Bender Robert & Associates’s AbbVie ABBV Stock Holding History

Bender Robert & Associates’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-7,466
Closed -$1.28M – 41
2024
Q2 		$1.28M Buy
+7,466
New +$1.24M 0.28% 27

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bender Robert & Associates's ABBV Position: Q1 2026 in Review

Bender Robert & Associates reduced its AbbVie (ABBV) stake by 13% in Q1 2026, selling an estimated $81K and leaving 2,393 shares worth $520K. The position accounts for 0.12% of the portfolio, ranked #31.

Bender Robert & Associates first reported a position in ABBV in Q2 2015 and has held it in 43 quarters since. The position peaked at $5.61M in Q4 2017. 4,078 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Bender Robert & Associates held 2,393 shares of AbbVie worth $520K as of Q1 2026.
  • Bender Robert & Associates sold 365 AbbVie shares in Q1 2026, an estimated $81K.
  • AbbVie made up 0.12% of Bender Robert & Associates's portfolio in Q1 2026, its #31 holding.
  • Bender Robert & Associates first reported a position in AbbVie in Q2 2015 and has held it in 43 quarters since.
  • Bender Robert & Associates's AbbVie position peaked at $5.61M in Q4 2017.
  • 4,078 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Bender Robert & Associates's 13F filing for Q1 2026, filed 23 Apr 2026.